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Retinal pigment epithelium (RPE) is a polarized cell layer critical for photoreceptor function and survival. The
unique physiology and relationship to the photoreceptors make the RPE a critical determinant of human
vision. Therefore, we performed a global expression proﬁling of native and cultured human fetal and adult
RPE and determined a set of highly expressed ‘signature’ genes by comparing the observed RPE gene pro-
ﬁles to the Novartis expression database (SymAtlas: http://wombat.gnf.org/index.html) of 78 tissues. Using
stringent selection criteria of at least 10-fold higher expression in three distinct preparations, we identiﬁed
154 RPE signature genes, which were validated by qRT-PCR analysis in RPE and in an independent set of
11 tissues. Several of the highly expressed signature genes encode proteins involved in visual cycle, mela-
nogenesis and cell adhesion and Gene ontology analysis enabled the assignment of RPE signature genes to
epithelial channels and transporters (ClCN4, BEST1, SLCA20) or matrix remodeling (TIMP3, COL8A2). Fifteen
RPE signature genes were associated with known ophthalmic diseases, and 25 others were mapped to
regions of disease loci. An evaluation of the RPE signature genes in a recently completed AMD genomewide
association (GWA) data set revealed that TIMP3, GRAMD3, PITPNA and CHRNA3 signature genes may have
potential roles in AMD pathogenesis and deserve further examination. We propose that RPE signature genes
are excellent candidates for retinal diseases and for physiological investigations (e.g. dopachrome tautomer-
ase in melanogenesis). The RPE signature gene set should allow the validation of RPE-like cells derived from
human embryonic or induced pluripotent stem cells for cell-based therapies of degenerative retinal diseases.
INTRODUCTION
Progressive retinal degenerative diseases, such as age-related
macular degeneration (AMD) and retinitis pigmentosa (RP),
are major causes of untreatable blindness and have a tremen-
dous social and ﬁnancial burden on society. As many as 30
million people worldwide are afﬂicted with AMD, and this
diagnosis is expected to increase dramatically in the coming
decades because of aging populations (1,2). AMD is an
aging-associated multifactorial disease that affects the
photoreceptor-retinal pigment epithelium (RPE)–choroid
interface in the macula and is caused by the interaction of
genetic susceptibility factors and environment (3). The RPE
is the source and the target of many retinal degenerative dis-
eases and defects in RPE function can affect the integrity
and viability of neighboring cells—primarily photoreceptors
(4–6).
The RPE is a polarized monolayer of epithelial cells that
separates the neural retina and the choroidal blood supply
and forms a highly selective barrier fundamentally important
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(7,8). This epithelium is derived from neural ectoderm and
forms a close anatomical relationship with the photoreceptors,
mimicking the neuronal–glial relationship observed in the
central nervous system (CNS). In the eye, light–dark tran-
sitions and circadian rhythms modulate the RPE transport of
nutrients, metabolic waste products, ions and ﬂuid between
the choroidal blood supply and the subretinal space surround-
ing the photoreceptor outer segments (9,10). High metabolic
activity and ongoing exposure to light makes the RPE particu-
larly vulnerable to oxidative damage. Not surprisingly,
abnormalities in RPE phagocytosis of rods and cones or in
the maintenance of the visual cycle can lead to retinal degener-
ation and photoreceptor cell death (11).
Disease processes affecting RPE/photoreceptor interaction
and causing RPE dysfunction have been subjects of intense
scrutiny (12–14). In vitro models of RPE have been derived
from native and cultured human cells, from fetal and postnatal
donor eyes, transformed cell lines and embryonic stem (ES)
cells (14–19). Cultured human RPE can be grown in large
quantities and used in biochemical and functional assays
(18, 20) or transplantation studies. However, the value of cul-
tured RPE depends on its ability to recapitulate functional and
genetic characteristics of the native tissue. We have previously
developed a primary human fetal RPE cell culture model that
mimics the normal physiology, function and structure of
native fetal and adult RPE, and thus is suitable for a wide
range of studies on diseases associated with retina/RPE inter-
actions (10,18,21–23).
The global expression proﬁle of human RPE will be valu-
able for elucidating its pivotal role in retinal degenerative
diseases (24). Hence, we have performed a comparative analy-
sis of transcriptomes from human fetal and adult RPE, primary
cultures and commonly used human cell lines and tissues. We
report a unique ‘signature’ set of 154 genes whose expression
levels distinguish RPE from other tissues or cell types. We
also describe a cross-sectional analysis of RPE ‘signature’
genes against an AMD genomewide association study
(GWAS) (25) with a goal of identifying candidate genes and
pathways relevant to AMD. Ingenuity analysis and RetNet
(www.sph.uth.tmc.edu/retnet/) were used to analyze RPE sig-
nature genes to identify novel candidate genes for RPE
disease. Our study provides an important discovery tool for
functional investigations of RPE/photoreceptor interaction
and establishes a molecular platform to evaluate RPE cells
for repair of degenerating retina.
RESULTS
Human RPE ‘gene signature’
We generated global expression proﬁles of native fetal and
adult human RPE, and of fetal primary cultures and compared
these with transcriptomes of adult transformed RPE cell lines
and of other human tissues (Fig. 1). Principle component
analysis (PCA) and hierarchical cluster analysis were ﬁrst
used to evaluate similarities or differences in gene expression
between samples from primary cultures and native RPE.
The hierarchical clustering dendrogram based on principal
components of 30 samples demonstrates that native human
tissues (fnRPE and anRPE) and cultured cells (fcRPE and
ARPE-19) cluster separately regardless of the sample source
(Fig. 2A). In contrast, biological (n ¼ 4) or technical replicates
(ARPE-19; n ¼ 8) in each RPE group cluster together. More
than 50% of the total variability in expression data is included
in PC1, PC2 and PC3 (Fig. 2B, C and see legend). Visual
inspection of PC1 versus PC2 (Fig. 2B) and PC2 versus PC3
(Fig. 2C) plots reveals distinct clusters separating the four
different RPE preparations.
To identify an expression proﬁle that distinguishes human
RPE from other cell types, we compared the expression of
native adult and fetal RPE and primary cultures of fetal RPE
against 78 different human tissues and cell cultures (26).
The relative expression (rEx) values (see Materials and
Methods) revealed a set of 154 highly expressed genes (171
probe sets) in anRPE, fnRPE and fcRPE (Fig. 3A and B).
We call these ‘signature’ genes as they together provide a
unique proﬁle of RPE functions. Gene ontology (GO) analysis
further identiﬁed several critical functional groups signiﬁ-
cantly over-represented in the ‘signature’ genes (P , 0.005).
These include (i) vision, perception of light and vitamin A
metabolism (e.g. CRX, EFEMP1, RPE65, SFRP5, SIX3,
TIMP3, BEST1, RDH11, RBP1); (ii) response to stimulus
and sensory perception (e.g. AHR, CDH3, GJA1, ENPP2,
PITPNA); (iii) oxidoreductase activity (e.g. PCYOX1, STCH,
ALDH1A3, CDO1, BDH2, FADS1); (iv) pigment
biosynthesis and melanin biosynthesis [e.g. GPR143, TYRP1,
dopachrome tautomerase (DCT), SILV]; (v) phagocytic
activity (LAMP2, VDP, GULP1); (vi) transporter activity
(e.g. SLC39A6, SLC4A2, SLC16A1, SLC16A4) (Fig. 3C and
Table 1).
Based on the rEx levels, the 154 RPE ‘signature genes’ in
anRPE, fn RPE, fcRPE and acRPE preparations can be clus-
tered into four groups (Fig. 4 and Supplementary Material,
Table S1). Cluster 1 consists of genes that are on average
three times more highly expressed in native fetal compared
with the native adult RPE. These genes are involved in extra-
cellular matrix (ECM) formation, tissue remodeling, cytoskele-
ton reorganization and trafﬁcking, and can be used as sentinels
for cell culture-induced alterations in gene expression. Cluster 2
identiﬁes genes whose expression levels are high and relatively
Figure 1. Experimental design. Four groups of native cells and primary RPE
cultures were used for the microarray analysis (a total of 30 samples): (ii) adult
native RPE (AN); (ii) native fetal RPE (FN); (iii) primary cultures of fetal RPE
(FC) at passage 1; (iv) ARPE-19 (AC), a transformed cell line. To determine
the effect of culture conditions on gene expression of FC and AC, RPE cells
were cultured on transwells or ﬂasks. A total of 12 human donor eyes were
used to collect adult and fetal native RPE cells (four donors in each case)
and to establish fetal RPE primary cultures (four donors).
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genes involved in visual cycle, pigment biosynthesis, transpor-
ter activity and cell signaling. Custer 3 is similar to Cluster 2,
but with lower levels of gene expression. Cluster 4 includes
an important group of 17 genes that exhibit 26–87 times
lower expression in ARPE-19 cells when compared with
native and fetal cultured RPE. Functional groups (GO terminol-
ogy) represented in this cluster include (i) transporters; (ii)
growth factors and transcriptional regulators; (iii) signaling pro-
teins and (iv) visual cycle components.
Validation of RPE ‘signature’ genes
Expression levels of RPE signature genes were validated by
qRT-PCR in preparations from donor RPE (n ≥ 2) and in a
panel of human tissues and cell cultures from native fetal
retina, native and cultured fetal choroid, brain, melanocytes,
colon, intestine, kidney, liver, lung, trachea, calu-3 cells, a
tissue-mix and testes. The correlation coefﬁcient between
log10-transformed qRT-PCR and the log10-transformed
microarray expression levels were calculated for each RPE
group. For the microarray data, the rEx value for each gene
was calculated relative to the median of the corresponding
gene in a validation panel of 11 tissues (Supplementary
Material, Table S1). Three tissues (native fetal retina, native
and cultured fetal choroid) were excluded from the validation
set because of their physical proximity to RPE and the possi-
bility of contamination by RPE. The mean rEx for each gene
by qRT-PCR in fetal-cultured RPE, adult-cultured RPE/
ARPE-19, fetal native RPE and adult native RPE samples
showed a signiﬁcant correlation (P , 0.0001) with the micro-
array data in each RPE sample type. The correlation coefﬁ-
cient is 0.74 for cultured fetal RPE, 0.94 for the adult
cultured/ARPE-19, 0.83 for fetal native RPE, and 0.76 for
native adult tissue.
Hierarchical clustering of tested samples (Fig. 5) demon-
strates a distinct segregation of RPE samples (shown above
the yellow line) from 14 other tested tissues, as revealed by
the expression of 150 signature genes. The qPCR levels of
RPE signature genes (Supplementary Material, Table S1)
segregate into two major clusters according to the level of
variation of their rEx between native and cultured RPE
groups and within each RPE group. Cluster 1 includes ‘com-
monly expressed RPE genes’ that are, for the most part,
three to four orders of magnitude more highly expressed in
the RPE samples relative to the validation set. The dashed
box in Cluster 2 indicates genes that are ≈100-fold more
highly expressed in native RPE (fetal and adult) when
compared with cultured RPE and with the validation set. In
contrast, the expression levels of ‘commonly expressed RPE
Figure 2. Hierarchical clustering (A), and biplots of the three predominant principal components [PC1, PC2, PC3], (B) and (C) demonstrate that RPE samples
separated into two major groups as a result of culture, regardless of the sample origin (adult or fetal). Microarray gene expression analysis of 54 675 probe sets
was performed using 30 samples from fetal cultured, fetal native, adult native RPE and ARPE-19 cells. Principal components analysis (which rotates the original
30 data vectors into a new set of 30 vectors whose principal components, or PCs, are uncorrelated and ordered by descending magnitude) was applied to reduce
the dimensionality of the data and allow for visualization and clustering. Data also show that all the RPE samples from the same culture or tissue category
grouped together, ruling out potential misclassiﬁcations. Ellipses indicate 50% conﬁdence levels for each tissue type. Percentage values next to each PC indicate
the proportion of total variation in the original 30 by 54 675 data matrix represented by each principal component. Thus, the three predominant components
represent the majority (54% ¼ 25.6 + 15.6 + 12.8) of the total variation among the 30 samples on the 54 675 probe sets (85). There is a greater heterogeneity
among the adult native RPE gene expression proﬁles, compared with the other three groups. Expression proﬁles under controlled culture conditions are expected
to be more homogeneous than those from native tissue from different individuals. The four adult native RPE tissues were from individuals with a 25 year age
range, while the fetal tissues were from a limited gestational age range (16–18 weeks).
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(excluding ARPE19; dotted box, Cluster 1) and therefore are
not substantially affected either by culturing or by the
choice of model (fetal versus adult or native versus cultured).
We suggest that these genes can be used as RPE markers.
Culturing RPE cells can alter the expression of ‘signature’
genes. To evaluate this further, we calculated the relative
decrease in expression for all signature genes in AC
(ARPE-19) and FC RPE relative to adult RPE. In both cases,
the median decrease is ≈3-fold. The expression of a given
gene was considered unchanged if it was similar to native
adult RPE expression. However, some genes express at drasti-
cally lower levels (up to 1000-fold lower) in ARPE-19, but
not in FC RPE (Supplementary Material, Table S1). In
ARPE-19, 74 of 150 of the signature genes are expressed at
lower levels when compared with adult native RPE. In compari-
son, only 34 of 150 are expressed at reduced level in FC RPE
when compared with adult native RPE.
Differential expression of selected RPE genes was validated
by immunoblot analysis. Protein levels of TYRP1, BEST1,
CDH3, CRX, CHRNA3, RPE65 were determined in fetal
RPE cultures (three donors) and ARPE-19 cell cultures
(Fig. 6A). As predicted by qRT-PCR and microarray analysis,
protein levels of TYRP1 were similar between the RPE
models, whereas the levels of other proteins, including
BEST1, CDH3, CRX, CHRNA3, RPE65, were dramatically
reduced in ARPE-19 cultures. Immunoblot analyses also
demonstrated high expression of RPE65, BEST1, SILV1,
CHD3, CHRNA3 and SERPIF1 proteins in RPE when com-
pared with other tissues tested (Fig. 6B).
Cross-sectional analysis of the RPE signature genes against
AMD–GWAS
Early changes in AMD include RPE dysfunction (27). To
check the potential contribution of RPE-enriched ‘signature’
genes to AMD, we examined  2.5 million genotyped and
imputed single nucleotide polymorphisms (SNPs) in 2157
AMD cases and 1150 controls (28). Among these SNPs, we
focused on those with at least 1% minor allele frequency
and within 100 kb of the 5′ and 3′ end of each of the 154
RPE ‘signature’ genes, resulting in a set of 33 096 SNPs for
evaluation. For each of these, we examined the association
with AMD in the GWAS data set and compared the observed
P-values with their chance expectations (assuming none of the
variants are associated with AMD; Fig. 7). The most signiﬁ-
cant association maps near the TIMP3 gene (rs5754221, P ¼
5 × 10
25), and other potentially interesting signals, are
observed near GRAMD3 (rs4836255, P ¼ 3 × 10
24),
PITPNA (rs17821234, P ¼ 4 × 10
24) and CHRNA3
(rs11072791, P ¼ 6 × 10
24). We note that genotyping of
additional AMD case–control samples (25) indeed validated
the association of SNPs near TIMP3 with AMD (P ¼ 10
211).
In addition to these four SNPs near 48 other genes show
slight association with AMD at a P-value of ,0.01 (Table 2)
and may be the candidates for further examination, given the
convergence of gene expression data (reported here) and the
genetic association data (from the GWAS). The functional
classiﬁcation of these 48 genes by DAVID (29) revealed 18
genes with a signal sequence at N terminus (Fig. 8). All 18
have a central hydrophobic region (red), N-terminal hydrophilic
region (green) and a C-terminal ﬂanking region (blue). Notably,
Figure 3. (A) Identiﬁcation of RPE signature genes common among native fetal, adult native and fetal cultured RPE cells compared with the expression the same
genes in the Novartis anatomically diverse data set (A). RPE-speciﬁc genes were determined through the selection of genes with relative expression (rEx) values
of 10 or greater in each RPE group when their mean expression values were compared with the median gene expression value of all 78 Novartis tissues (SymA-
tlas, http://wombat.gnf.org/index.html). (B) Venn diagram showing the number of genes with rEx ≥ 10 in AN, FN and FC RPE preparations and the number of
common ‘signature’ genes between these lists when compared with the Novartis panel. (C) GO Biological process functional groups overrepresented in the RPE
signature as determined by the EASE analysis (EASE score P,0.005).
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a values of RPE signature genes
b (154) with rEx ≥ 10 compared to the Novartis data set determined by microarray analysis
Gene symbol Gene name Probe set ID Fold-change
AN (n ¼ 4) FN (n ¼ 4) FC (n ¼ 4) AC (n ¼ 8) PCR Val
ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 202381_at 13.9 26.8 52.4 50.3
ADCY9 Adenylate cyclase 9 204497_at 21.3 29.7 11.2 17.5
AHR Aryl hydrocarbon receptor 202820_at 12.1 13.2 11.1 28.7 †
ALDH1A3 Aldehyde dehydrogenase 1 family, member A3 203180_at 37.2 342.3 51.4 247.5
ANKRD12 Ankyrin repeat domain 12 216550_x_at 22.8 22.0 10.4 12.8
APLP1 Amyloid beta (A4) precursor-like protein 1 209462_at 28.7 80.1 38.8 48.4
ARL6IP1 ADP-ribosylation factor-like 6 interacting protein 1 211935_at 14.1 23.5 12.2 9.3
ARMC9 Armadillo repeat containing 9 219637_at 12.0 10.1 16.3 13.0
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 210980_s_at 13.9 31.3 13.3 18.2
ATF1 Activating transcription factor 1 222103_at 10.4 24.3 15.7 23.3 †
BAT2D1 BAT2 domain containing 1 211947_s_at 14.4 13.3 11.1 11.1
BCLAF1 BCL2-associated transcription factor 1 201101_s_at 16.4 13.7 25.8 15.8 †
BDH2 3-Hydroxybutyrate dehydrogenase, type 2 218285_s_at 13.0 22.6 13.6 16.9
BEST1 Bestrophin 1 207671_s_at 53.5 167.6 31.4 1.5
BHLHB3 Basic helix–loop–helix domain containing, class B, 3 221530_s_at 11.9 16.2 11.9 14.6
BMP4 Bone morphogenetic protein 4 211518_s_at 61.8 158.0 38.4 45.6
C1orf108 Akirin 1 217893_s_at 10.6 14.6 16.1 14.7
C20orf19 Chromosome 20 open-reading frame 19 219961_s_at 10.6 21.4 14.7 15.2
CALU Calumenin 200755_s_at 11.3 25.2 67.6 53.8
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) 201131_s_at 13.8 51.7 26.3 8.1 †
CDH3 Cadherin 3, type 1, P-cadherin (placental) 203256_at 10.6 64.6 30.7 3.4
CDO1 Cysteine dioxygenase, type I 204154_at 14.4 57.9 10.5 3.0
CHRNA3 Cholinergic receptor, nicotinic, alpha 3 210221_at 35.0 52.8 39.1 1.2
CHRNA3 Cholinergic receptor, nicotinic, alpha 3 211772_x_at 28.3 32.2 29.5 0.9
CLCN4 Chloride channel 4 214769_at 45.6 107.0 21.8 16.4
COL8A2 Collagen, type VIII, alpha 2 221900_at 12.2 132.0 38.4 21.0
COX15 COX15 homolog 221550_at 13.6 14.2 18.7 13.6
CRIM1 Cysteine-rich transmembrane BMP regulator 1 202552_s_at 21.8 27.6 28.5 55.2
CRIM1 Cysteine-rich transmembrane BMP regulator 1 202551_s_at 11.7 12.3 17.9 35.4
CRX Cone-rod homeobox 217510_at 41.9 14.3 11.8 0.2
CSPG5 Chondroitin sulfate proteoglycan 5 (neuroglycan C) 39966_at 19.2 102.8 22.4 5.0
CTBP2 C-terminal binding protein 2 201218_at 12.8 29.1 11.0 10.2
CYP20A1 Cytochrome P450, family 20, subfamily A, polypeptide 1 219565_at 10.2 15.6 18.0 21.2
DAP3 Death-associated protein 3 208822_s_at 12.4 27.0 29.3 27.9
DCT Dopachrome tautomerase 205337_at 12.6 304.6 131.2 12.0
DCUN1D4 DCN1, defective in cullin neddylation 1 212855_at 10.6 19.4 17.4 24.5
DEGS1 Degenerative spermatocyte homolog 1 209250_at 10.7 10.8 18.3 22.7 †
DHPS Deoxyhypusine synthase 207831_x_at 10.8 19.8 15.8 12.7
DIXDC1 DIX domain containing 1 214724_at 10.9 18.5 13.2 29.8
DMXL1 Dmx-like 1 203791_at 12.4 50.4 14.5 14.4
DNAJB14 DnaJ (Hsp40) homolog, subfamily B, member 14 219237_s_at 13.6 14.6 10.2 10.1
DUSP4 Dual speciﬁcity phosphatase 4 204014_at 75.8 268.0 427.5 40.0
DUSP4 Dual speciﬁcity phosphatase 4 204015_s_at 22.8 46.1 103.6 10.7
DZIP1 DAZ interacting protein 1 204557_s_at 10.7 32.7 26.8 19.0
EFEMP1 EGF-containing ﬁbulin-like extracellular matrix protein 1 201843_s_at 28.3 51.0 28.0 111.8
EFEMP1 EGF-containing ﬁbulin-like extracellular matrix protein 1 201842_s_at 22.5 28.8 23.9 52.6
EFHC1 EF-hand domain (C-terminal) containing 1 219833_s_at 16.0 38.6 41.3 54.1
EID1 EP300 interacting inhibitor of differentiation 1 211698_at 16.6 26.7 13.7 25.2
ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase 2 209392_at 33.2 71.8 12.1 39.0
FADS1 Fatty acid desaturase 1 /// fatty acid desaturase 3 208963_x_at 15.0 42.0 39.5 27.6
FAM18B Family with sequence similarity 18, member B 218446_s_at 14.1 17.9 16.7 18.0
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2FGFR2 Fibroblast growth factor receptor 2 203638_s_at 21.3 148.4 45.8 1.0
FOXD1 Forkhead box D1 206307_s_at 10.8 88.4 30.2 30.0
FRZB Frizzled-related protein 203698_s_at 84.3 314.0 183.7 0.4
FRZB Frizzled-related protein 203697_at 38.9 115.3 53.6 0.1
GAS1 Growth arrest-speciﬁc 1 204457_s_at 12.5 51.6 19.5 33.4
GEM GTP-binding protein overexpressed in skeletal muscle 204472_at 23.3 53.1 16.7 52.3
GJA1 Gap junction protein, alpha 1, 43 kDa 201667_at 11.6 50.7 31.7 38.6
GOLPH3L Golgi phosphoprotein 3-like 218361_at 13.4 17.3 15.2 18.7 †
GPM6B Glycoprotein M6B 209170_s_at 25.1 62.4 11.3 0.2
GPNMB Glycoprotein (transmembrane) nmb 201141_at 17.5 32.3 64.1 70.0
GPR143 G protein-coupled receptor 143 206696_at 12.6 153.8 64.8 53.6
GRAMD3 GRAM domain containing 3 218706_s_at 15.1 18.1 15.4 17.5
GULP1 GULP, engulfment adaptor PTB domain containing 1 215913_s_at 18.4 103.4 84.2 25.3
GULP1 GULP, engulfment adaptor PTB domain containing 1 204235_s_at 15.4 81.9 35.6 14.2
GULP1 GULP, engulfment adaptor PTB domain containing 1 204237_at 19.8 82.7 38.8 19.0
HSP90B1 Heat shock protein 90 kDa beta (Grp94), member 1 216449_x_at 15.5 34.7 110.9 61.1
IFT74 Intraﬂagellar transport 74 homolog (Chlamydomonas) 219174_at 36.7 73.5 44.2 73.5
IGF2BP2 Insulin-like growth factor 2 mRNA-binding protein 2 218847_at 10.4 38.0 20.3 18.3
ITGAV Integrin, alpha V 202351_at 31.4 53.1 29.5 47.5
ITM2B Integral membrane protein 2B 217731_s_at 18.6 21.8 13.5 27.6 N
KLHL21 Kelch-like 21 (Drosophila) 203068_at 14.8 25.8 23.6 24.9
KLHL24 Kelch-like 24 (Drosophila) 221986_s_at 12.9 22.5 23.7 15.0
LAMP2 Lysosomal-associated membrane protein 2 200821_at 10.6 20.9 12.6 19.5
LAPTM4B Lysosomal protein transmembrane 4 beta 208029_s_at 12.0 20.9 18.5 13.8
LAPTM4B Lysosomal protein transmembrane 4 beta 214039_s_at 13.6 18.3 14.8 12.0
LGALS8 Lectin, galactoside-binding, soluble, 8 208933_s_at 15.7 23.3 16.2 31.8 †
LHX2 LIM homeobox 2 206140_at 36.7 335.8 348.6 161.1
LIMCH1 LIM and calponin homology domains 1 212328_at 10.1 29.6 14.5 50.1
LIN7C Lin-7 homolog C (C. elegans) 221568_s_at 22.6 37.3 18.1 27.7
LOXL1 Lysyl oxidase-like 1 203570_at 21.7 233.9 195.5 243.1
LSR Lipolysis-stimulated lipoprotein receptor 208190_s_at 16.7 15.3 11.6 10.9
MAB21L1 mab-21-like 1 (C. elegans) 206163_at 20.6 70.5 41.9 87.3
MANEA Mannosidase, endo-alpha 219003_s_at 14.7 30.8 21.6 27.5
MAP9 Microtubule-associated protein 9 220145_at 39.6 103.1 57.2 40.5
MBNL2 Muscleblind-like 2 (Drosophila) 203640_at 10.9 10.4 13.9 16.3 †
MED8 Mediator complex subunit 8 213126_at 19.5 39.9 23.0 25.7
MET Met proto-oncogene (hepatocyte growth factor receptor) 203510_at 64.0 224.2 78.0 191.5
MFAP3L Microﬁbrillar-associated protein 3-like 205442_at 49.1 60.3 46.1 56.2
MPDZ Multiple PDZ domain protein 213306_at 10.5 22.4 12.1 16.5
MPHOSPH9 M-phase phosphoprotein 9 215731_s_at 14.3 31.9 12.3 15.0
MPHOSPH9 M-phase phosphoprotein 9 206205_at 14.2 23.7 19.5 15.0
MYRIP Myosin VIIA and Rab interacting protein 214156_at 97.7 95.6 51.2 47.0
NAV3 Neuron navigator 3 204823_at 13.3 128.0 22.9 27.7
NDC80 NDC80 homolog, kinetochore complex component 204162_at 11.8 20.3 11.2 6.7
NEDD4L Neural precursor cell expressed 212448_at 11.5 23.3 17.4 9.1
NOL8 Nucleolar protein 8 218244_at 14.1 39.4 33.7 32.6 N
NRIP1 Nuclear receptor interacting protein 1 202600_s_at 32.5 50.2 22.1 38.2
NUDT4 Nudix (nucleoside diphosphate-linked moiety X) 212183_at 11.0 11.0 13.5 29.6 †
OSTM1 Osteopetrosis-associated transmembrane protein 1 218196_at 10.1 13.5 12.4 11.5
PAK1IP1 PAK1 interacting protein 1 218886_at 14.1 31.2 17.8 31.0
PCYOX1 Prenylcysteine oxidase 1 203803_at 16.6 16.4 22.8 23.6
PDPN Podoplanin 221898_at 14.8 81.2 30.7 26.7
PDZD8 — 213549_at 10.6 29.6 15.1 11.8
PHACTR2 Phosphatase and actin regulator 2 204049_s_at 14.5 40.0 10.6 24.8
PITPNA Phosphatidylinositol transfer protein, alpha 201191_at 29.2 63.3 11.3 9.2
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Gene symbol Gene name Probe set ID Fold-change
AN (n ¼ 4) FN (n ¼ 4) FC (n ¼ 4) AC (n ¼ 8) PCR Val
PKNOX2 PBX/knotted 1 homeobox 2 222171_s_at 11.9 47.0 13.9 1.5
PLAG1 Pleiomorphic adenoma gene 1 205372_at 10.2 43.9 14.6 3.0
PLCB4 Phospholipase C, beta 4 203896_s_at 11.8 30.1 27.2 95.7
PLOD2 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 202620_s_at 13.4 11.1 82.3 82.4
PRNP Prion protein 201300_s_at 12.1 18.0 10.3 14.6
PSME4 Proteasome (prosome, macropain) activator subunit 4 212219_at 13.1 15.2 20.4 19.1
PTGDS Prostaglandin D2 synthase 21 kDa (brain) 211663_x_at 11.2 14.9 10.6 1.2
PTPRG Protein tyrosine phosphatase, receptor type, G 204944_at 15.8 55.4 13.4 7.3
RAB38 RAB38, member RAS oncogene family 219412_at 14.1 75.5 15.1 19.3
RBM34 RNA-binding motif protein 34 214943_s_at 11.4 15.2 34.4 18.3 †
RBP1 Retinol-binding protein 1, cellular 203423_at 31.7 61.3 15.5 6.5
RDH11 Retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 217776_at 24.4 17.4 18.0 12.4
RHOBTB3 Rho-related BTB domain containing 3 202976_s_at 11.5 17.3 11.7 9.0
RNF13 Ring ﬁnger protein 13 201780_s_at 12.3 18.6 11.2 26.9
RPE65 Retinal pigment epithelium-speciﬁc protein 65 kDa 207107_at 277.1 375.7 13.3 8.5
RRAGD Ras-related GTP binding D 221524_s_at 34.8 65.8 30.0 37.4
SAS10 UTP3, small subunit (SSU) processome component 209486_at 12.1 22.3 25.2 26.5 N
SCAMP1 Secretory carrier membrane protein 1 212417_at 20.7 35.3 15.5 21.6
SDC2 Syndecan 2 212158_at 18.3 53.8 36.0 31.8
SEMA3C Sema domain, short basic domain, (semaphorin) 3C 203789_s_at 11.8 50.7 46.5 66.8
SERPINF1 Serpin peptidase inhibitor, 202283_at 36.1 51.0 36.2 20.5
SFRP5 Secreted frizzled-related protein 5 207468_s_at 40.8 233.6 23.3 2.0
SGK3 Chromosome 8 open-reading frame 44 / 220038_at 43.5 159.3 26.9 49.6
SIL1 SIL1 homolog, endoplasmic reticulum chaperone 218436_at 10.4 14.2 20.5 28.0
SILV Silver homolog (mouse) 209848_s_at 14.5 104.5 71.8 8.9
SIX3 SIX homeobox 3 206634_at 10.5 36.1 11.6 13.7
SLC16A1 Solute carrier family 16, member 1 202235_at 27.6 64.5 46.5 41.1
SLC16A1 Solute carrier family 16, member 1 202234_s_at 13.4 25.8 17.8 19.2
SLC16A1 Solute carrier family 16, member 1 209900_s_at 60.1 113.2 95.3 78.1
SLC16A4 Solute carrier family 16, member 1 205234_at 71.1 83.6 12.8 93.5
SLC24A1 Solute carrier family 24 206081_at 50.6 16.1 15.2 13.2
SLC39A6 Solute carrier family 39 (zinc transporter), member 6 202088_at 13.6 24.4 16.8 17.4
SLC4A2 Solute carrier family 4, anion exchanger 202111_at 20.9 104.6 35.8 64.8
SLC6A15 Solute carrier family 6 (neutral amino acid transporter) 206376_at 21.4 128.7 171.9 12.8
SLC6A20 Solute carrier family 6 (proline IMINO transporter) 219614_s_at 35.2 156.9 21.8 5.3
SMAD6 SMAD family member 6 207069_s_at 13.3 37.2 27.8 41.3
SMC3 Structural maintenance of chromosomes 3 209258_s_at 13.9 23.7 14.7 13.5
SORBS2 Sorbin and SH3 domain containing 2 204288_s_at 22.5 79.6 15.5 22.1
SOSTDC1 Sclerostin domain containing 1 213456_at 54.7 598.7 46.2 0.3
SPAST Spastin 209748_at 10.1 22.8 11.8 13.6
STAM2 Signal transducing adaptor molecule 209649_at 32.0 41.4 45.5 49.7
STCH Heat shock protein 70 kDa family, member 13 202557_at 11.0 14.9 18.1 11.9
SULF1 Sulfatase 1 212354_at 16.1 84.4 14.4 9.0
SULF1 Sulfatase 1 212353_at 20.9 107.6 14.3 8.9
TAX1BP1 Tax1 213786_at 12.9 28.7 12.3 15.0
TFPI2 Tissue factor pathway inhibitor 2 209278_s_at 155.9 169.2 31.2 894.7
TIMP3 TIMP metallopeptidase inhibitor 3 201147_s_at 14.9 22.8 28.8 58.1
TIMP3 TIMP metallopeptidase inhibitor 3 201150_s_at 25.6 31.1 20.7 35.6
TRPM1 Transient receptor potential cation channel 206479_at 32.2 229.0 43.0 23.0
TTLL4 Tubulin tyrosine ligase-like family, member 4 203702_s_at 14.5 157.0 42.9 6.1
TTR Transthyretin 209660_at 178.8 155.1 49.2 1.8
TYRP1 Tyrosinase-related protein 1 205694_at 234.8 307.3 222.9 191.8
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2coding regions of these genes include many variants that poten-
tially could contribute to protein misfolding.
In a separate analysis, we utilized a catalog of SNPs [called
expression quantitative trait loci (eQTLs)] known to be associ-
ated with expression levels of speciﬁc genes (30). From this cat-
alogue, we selected a list of 44 SNPs (Supplementary Material,
Table S2) associated with expression levels of some of the
genes in the RPE signature set (P , 10
27). Four of these
SNPs exhibited nominal association with AMD at P , 0.05
(compared with two expected by chance); these eQTLs
are rs12150474 (associated with expression of PHACTR2 at
P , 10
27 and with AMD with P ¼ 0.007); rs7105701
(RAB38 with P , 10
27; AMD with P ¼ 0.01); rs1483539
(LGALS8 with P , 10
28; AMD with P ¼ 0.03) and
rs2449517 (LAPTM4B with P , 10
28; AMD with P ¼ 0.04).
Role of DCT in RPE physiology
Epithelia are characterized by the asymmetric distribution of
plasma membrane proteins. This polarity fundamentally con-
tributes to a range of functions that allow the epithelium to
support the health and integrity of surrounding cells. The
present data show that DCT is highly expressed in human
RPE (Table 1; Supplementary Material, Fig. S1). Previous
studies have indicated a role for this gene product in
pigment development and the modulation of cell responses
to oxidative stress (31,32). In Figure 9A, we used a lentivirus
system to deliver speciﬁc shRNA to reduce DCT levels (clone
38) by ≈75% in hfRPE. A similar reduction was observed in
two additional experiments. This treatment caused a signiﬁ-
cant reduction in the transepithelial resistance (TER) of
conﬂuent monolayers from 842+222 to 328+171 V cm
2
(n ¼ 6; P , 0.05). A comparison of Fig. 9C and F show that
transduction of hfRPE cells with DCT38 clone shRNA a dra-
matically reduced intracellular DCT levels (Fig. 9F).
Reduction of DCT levels also led to a signiﬁcant reorganiz-
ation of fully polarized RPE cytoskeleton. For example, a
comparison of Figure 9D and G show that the apical localiz-
ation of ezrin is totally disrupted with an apparent loss of its
normal apical membrane polarity. Finally, Figure 9E and H
show RPE F-actin ﬁbers are disrupted to a more diffuse
pattern throughout the cells. These data indicate that DCT, a
highly expressed human RPE signature gene, is critical for
the maintenance of normal epithelial phenotype.
DISCUSSION
The RPE is fundamentally important for retinal development
and function, and is a critical focus of retinal degenerative dis-
eases and therapeutic intervention. Although RPE is function-
ally distinct from other epithelial cells and its pathophysiology
is under intense investigation, relatively little is known about
the set of genes that distinguish the RPE phenotype. The
gene expression proﬁle of a cell should reﬂect its morphologi-
cal and functional speciﬁcity as well as molecular and physio-
logical signaling pathways. The present study provides, for the
ﬁrst time, a speciﬁc gene expression signature of normal
human RPE. We generated global expression proﬁles of
human RPE (native and cultured cells) and identiﬁed 154
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Human Molecular Genetics, 2010, Vol. 19, No. 12 2475genes that exhibit 10-fold or higher expression when
compared with the median of Novartis data set of various tran-
scriptomes. Somewhat lesser stringent criteria of 5-fold or
higher expression increased the list of RPE genes to 919
probe sets. We suggest that the 154 highly expressed genes,
reported here, can serve as a ‘unique’ functional signature of
RPE and can discriminate it from other epithelia or cell types.
BecauseofRPE’srelevancetoretinal disease,theRPE ‘signa-
ture’ gene set is of value for identifying candidate genes for
genetic analysis or physiological studies. Ingenuity pathway
analysis, together with the RetNet database (www.sph.uth.tmc.
edu/retnet/home.htm), revealed 17 RPE signature genes that are
involved in ocular disorders (TYRP1, SIL1, BEST1, COL8A2,
EFEMP1, LOXL1, SERPINF1, BMP4, VEGFA, TIMP3,
CHRNA3, PRNP, RPE65, CRX, GPNMB, CDH1, CDH3). In
addition, our analysis of RPE signature genes identiﬁed a
number of newly discovered disease-associated genes. For
example, GRP143 was not included by ingenuity in the list of
disease-associated genes, but mutations in this gene were
reported to cause X-linked ocular albinism (OA1)( 33–35).
Another example is a discovery of two SNPs in the LOXL1
gene,recentlyassociatedwithstronggeneticriskforpseudoexfo-
liation (PEX) syndrome and PEX glaucoma and involved in the
formation of choroidal neovascularization (36,37). Using the
RetNet database (http://www.sph.uth.tmc.edu/retnet/), we also
identiﬁed 25 of the RPE signature genes within the critical
genomic region for retinal degenerative disease loci (Table 3).
The disease-causing genes within these loci have not been ident-
iﬁed, but the signature genes should be considered as possible
candidates, given the critical functional interactions between
the RPE and the neural retina. For example, neuroglycan C
plays an important role in retinal development and is found to
be up-regulated in a mouse model of retinal degeneration (38).
In addition, PTPRG might be a candidate for AMD (GWAS
P ¼ 0.00065; Table 2). Another interesting example is the
disease-associated locus MCDR3 (macular dystrophy, retinal 3)
that includes RPE signature genes SCAMP1 and RHOBTB3.
These two genes play a major role in regulating cell trafﬁc,
Figure 4. Cluster analysis performed on the proﬁles of 154 RPE-speciﬁc genes (171 probe sets) determined from microarray analysis on adult native RPE (AN)
tissues, native fetal tissues (FN), fetal cultured RPE (FC) and ARPE-19 (AC). (A) Gene clusters (Cl 1–Cl 4) reﬂect different relative expression (rEx) patterns of
the RPE-speciﬁc genes for each of the four RPE preparations. (B) Each horizontal colored band represents mean rEx of a single gene in each RPE preparation
with the color-bar, showing the numerical rEx value. The cluster dendrogram on the right-hand side of the heat map groups the genes into the clusters represented
in (A). (C) Log–log plot of signature gene-rEx of fetal native (FN - vertical axis 0-600 of rEx values) and adult native (AN - horizontal axis 0-600 of rEx values)
RPE. Genes above the unity line have a higher expression level in fetal native compared with adult native RPE.
2476 Human Molecular Genetics, 2010, Vol. 19, No. 12endocytosis andexocytosis (39,40), and mutations in these genes
c o u l dd i s r u p tt h ep o l a r i t yo fR P Ea n df u n c t i o nl e a d i n gt or e t i n a l
(photoreceptor) degeneration.
A surprisingly large number of genes (currently 32) in the
RPE signature set have been implicated as potential markers
for different types of cancers, and therefore may be critical
for the regulation of important RPE functions, including pro-
liferation, migration or signaling. For example, prostaglandin
D2 synthase (PTGDS) is a key enzyme in arachidonic acid
metabolism and is repressed in premalignant stages of oral epi-
thelial cancers (41). This enzyme is a melanocyte marker that
is also elevated in retinal detachments and associated with
open-angle glaucoma (42). Syndecan-2 is associated with
AMD (Table 2) and found to be over expressed in hepatocel-
lular carcinomas, colon carcinomas, and is involved in the sup-
pression of lung carcinoma metastasis (43,44). Podoplanin
(PDPN) is a novel marker for human well-differentiated kera-
tinizing squamous cell carcinomas of the epithelium (45,46)
and dendritic sarcomas (47). It is also a candidate disease
gene for Leber congenital amaurosis (Table 3). Mutations in
ADAM9 (Table 2) have been implicated in the pathogenesis
retina/RPE attachment in cone-rod dystrophies (48). In
addition, frizzle-related protein 5 (SFRP5) is a known
inhibitor of the WNT pathway and plays a crucial role in
the development of human cancers and is a candidate gene
for X-linked retinal dystrophies (49,50).
Cluster analysis is an important tool for distinguishing the
genetic architecture of RPE models. For example, Fig. 4
(Clusters 2 and 3) summarizes a set of genes that are expressed
at approximately the same level across all native and cultured
tissues. These genes, although expressed at two different
levels, are all highly expressed when compared with the
Novartis transcriptome and invariant with developmental
stage or culture conditions. Therefore, we suggest that they
represent a kernel of genes minimally required for RPE pheno-
type. In addition, we found a group of RPE genes (n ¼ 26) that
are signiﬁcantly under expressed in ARPE-19 cultured cells
when compared with native tissue and primary culture
(Fig. 4A, Cluster 4). Previously, it has been shown that these
transformed cell lines lack functional characteristics of native
RPE. For example, they have relatively low TER, no visible
pigmentation and practically no apical microvilli (51,52).
The genes showing low ARPE19 expression can be grouped
into the following functional categories: (i) transporter activity;
(ii) growth factors and transcriptional regulators; (iii) ECM
formation and tissue remodeling; (iv) retinoic and fatty acids
metabolism and (v) formation of tight junctions, trafﬁcking
and melanogenesis. Not surprisingly, the lack of expression
Figure 5. Cluster dendrogram obtained from hierarchical clustering of RPE signature genes determined by qRT-PCR. The dendrogram represents signature gene
transcript levels (DCt compared with ﬁve housekeeping genes) for four RPE preparations (AN, n ¼ 2; FN, n ¼ 3; FC, n ¼ 3; and AC/ARPE-19, n ¼ 2), and a
validation set of 14 other tissues and cultures demarcated by the horizontal dotted line. Starting at the bottom of the ﬁgure, the validation tissues are: the brain,
colon, intestine, kidney, liver, lung testes, trachea, calu3, tissue mix, melanocyte, human fetal retina, human fetal choroid and cultured human choroid RPE. The
later three tissues are adjacent to RPE and may therefore contain RPE contamination and are therefore not included in the fold-change calculations. RPE sig-
nature genes are plotted horizontally and the tissues are plotted vertically. Each vertical colored band corresponds to expression values for one of the 150 genes in
different tissue preparations, relative to the mean value for that gene. Cluster analysis clearly separates native RPE, cultured RPE and ‘other tissues.’ Cluster I
contains a common set of genes, most of which are three to four orders of magnitude more highly expressed in RPE tissue compared with their counterparts in the
validation set. Cluster II highlights (dotted box) genes that are ≈100-fold more highly expressed in native compared with culture RPE.
Human Molecular Genetics, 2010, Vol. 19, No. 12 2477of these proteins can signiﬁcantly alter normal function of RPE
cells (53–57). For example, mice with deletion of ALDH1A3
(Cluster 5), a key factor regulating synthesis of retinoic acid,
die just after birth due to altered epithelial–mesenchymal
development (58). A reduced level of COL8A2 could affect
formation of ECM by RPE, which in turn deregulates ability
of the cell to proliferate and differentiate (53). Lack of
GPR143 affects melanosomal biogenesis and trafﬁcking
leading to the X-linked ocular albinism (OA1) in humans
(33,35,59). Reduced expression of these genes in ARPE-19 is
probably due to a combination of factors including contami-
nation of the primary cultures by ﬁbroblasts, an excessive
number of passages and further de-differentiation compared
with primary cultures of fetal human RPE.
Many of the genes in the signature set are differentially
expressed between native fetal and adult RPE (Fig. 4A, Cluster
1).Thisexpressiondifference,conﬁrmed by PCR,isparticularly
high for the following genes located well above the unity line in
Figure 4C: DCT, GPR143, SOSTDC1, COL8A2, FOXD1, SILV
and FGFR2. Mutations in COL8A2 gene are linked to Fuchs’
endothelial dystrophy and posterior polymorphous dystrophy
(60). Mutations in FGFR2 gene are associated with a variety
of CNS disorders such as Crouzon syndrome, Pfeiffer syndrome
and Craniosynostosis. Several of these genes may be develop-
mentally important and related to pigment synthesis. Mutations
of GPR143 can affect pigment production in the eye and cause
optic changes associated with albinism (35,59) (vide supra).
The DCT gene product is another example of an enzyme
involvedinmelaninbiosynthesisthatcontributestoRPEhomeo-
stasis by detoxifying DOPA-derived metabolites (61). Modu-
lation of DCT levels by siRNA substantially affects
proliferation in cortical neural progenitor cells (62)a n di s
involved in multidrug resistance (63,64).
The present experiments (Fig. 9) indicate a novel function
for DCT in maintaining epithelial polarity and tight junction
integrity. The shRNA-induced decrease in DCT protein
expression signiﬁcantly decreased the total tissue resistance,
which in RPE is mainly determined by the resistance of the
paracellular (tight junction) pathway (65). Dissolution of epi-
thelial junctions is associated with proliferation and migration
and is a precursor of epithelial to mesenchymal transitions, a
hallmark of the progression to cancer (65). The reorganization
of the cytoskeleton and the loss of polarity following the
decrease in DCT levels further support this notion. This
RPE signature gene joins several recently identiﬁed micro-
RNAs enriched in RPE (65) that help maintain a quiescent
and polarized state throughout the life of the organism.
Recent linkage and association studies have revealed a
number of single nucleotide or other genetic variants that
Figure 6. (A) Proteins levels of TYRP1, BEST1, CDH3, CRX, CHRNA3, RPE65 in fcRPE (FC1–FC3, n ¼ 3) and ARPE-19 (AC1) cells. Similar to the
qRT-PCR data, the TYRP1 levels were not different between the RPE models. The levels of BEST1, CDH3, CHRNA3, RPE65 proteins were dramatically down-
regulated in ARPE-19 cultures. (B) The levels of RPE65, BEST1, SILV1, CHD3, CHRNA3, SERPIF1 proteins in fetal native and cultured RPE, ARPE-19,
choroids, retina, endothelial cells (HUVEC), smooth muscle cells (SMC), ﬁbroblasts (FB) and circulating monocytes (MN).
Figure 7. Quantile–quantile (Q–Q) plot of predicted versus observed P-value
of SNP’s distribution between the AMD and control groups within the region
of each gene with 100 kb extension on either side of the 5′ and 3′ ends of each
gene. The ﬁgure was generated based on the 33 096 SNPs from GWAS study.
Each point on the plot represents an SNP. X-axis is the ordered expected
P-values using a 2log10 scale, and the y-axis is the observed P-value using
a similar scale. Statistical package R 2.8.0 (http://www.r-project.org/) was
used to generate the plots.
2478 Human Molecular Genetics, 2010, Vol. 19, No. 12exhibit major (CFH region at 1q32 and ARMS2 region at
10q26) or minor (C2/CFB, C3, CFI, ABCA4) contributions
to AMD susceptibility (66). A number of additional loci
were recently suggested to exhibit signiﬁcant genetic associ-
ation in a GWAS (25); however, their relevance to AMD
would require functional validation. Our cross-sectional analy-
sis that examined SNPs near the 154 RPE signature genes for
association in the AMD–GWAS data set revealed four genes,
including TIMP3. We also identiﬁed three additional genes
such as CHRNA3, GRAMD3 and PITPNA that deserve
further investigations for their potential role in AMD etiology.
CHRNA3 encodes the nicotinic cholinergic receptor alpha 3, a
member of the nicotinic acetylcholine receptor family, which
plays an important role in calcium regulation, neuronal devel-
opment and cognitive functions (67,68). Mutations in this gene
lead to dysfunction associated with various neurodegenerative
disorders, including Alzheimer’s disease, Parkinson’s, epi-
lepsy and autism. In RPE, deregulation of Ca
2+ signaling
could signiﬁcantly impair overall cell physiology, for
example, leading to abnormal ﬂuid absorption, or to the abnor-
mal secretion of different growth factors, including VEGF,
leading to the development of neovascular AMD (69,70).
Further bioinformatic analysis (71) of the 48 RPE signature
genes that showed nominal association with AMD revealed
Table2. Forty-eightgenes fromthe RPEsignaturelistlocated inthe regions(loci)carryingSNP’ssigniﬁcantlyassociatedwithAMD (P , 0.01)as determinedby
GWAS
SNP P-value Chromosome Position RPE gene Gene in the region
rs5754221 4.60E 2 05 22 31433455 TIMP3 SYN3,TIMP3
rs4836255 0.0003231 5 125765866 GRAMD3 RNUXA,ALDH7A1,GRAMD3
rs17821234 0.0003802 17 1383000 PITPNA TBC1D3B,CCL3L1,CCL4L2,PRPF8,MYO1C,MGC14376,CCL3L3,PITPNA,
YWHAE,SKIP,CCL4L1,CRK,SLC43A2,SCARF1,WDR81,RILP
rs11072791 0.0005563 15 76784131 CHRNA3 LOC123688,ADAMTS7,CHRNA3,CHRNB4,MORF4L1,CHRNA5,PSMA4
rs1451610 0.0005822 11 87623241 RAB38 RAB38,CTSC
rs2043083 0.0006062 3 150638008 WWTR1 TM4SF1,TM4SF4,WWTR1,TM4SF18
rs4688645 0.0006565 3 61595936 PTPRG PTPRG
rs17078339 0.0008899 3 45797441 SLC6A20 SLC6A20,FYCO1,LZTFL1,CXCR6,CCR9,SACM1L,LIMD1
rs2083845 0.001021 18 9277340 ANKRD12 ANKRD12,NDUFV2,TWSG1,RALBP1
rs2207189 0.001445 1 169655540 BAT2D1 FMO1,BAT2D1,FMO4
rs17102387 0.001514 10 123406568 FGFR2 ATE1,FGFR2
rs10033615 0.001775 4 171137594 MFAP3L AADAT,MFAP3L
rs1463729 0.001846 9 125921269 LHX2 NEK6,LHX2,DENND1A
rs10901850 0.001952 10 126697871 CTBP2 ZRANB1,CTBP2,KIAA0157
rs1883931 0.002225 6 52547818 EFHC1 TRAM2,EFHC1,GSTA2,PAQR8,TMEM14A
rs1479024 0.00234 12 76843663 NAV3 NAV3
rs11130146 0.002518 3 47682816 CSPG5 CSPG5,DHX30,SCAP,TMEM103,SMARCC1,MAP4
rs4935917 0.002532 11 124672022 PKNOX2 FEZ1,PKNOX2,LOC219854
rs12375908 0.002636 9 88816922 GAS1 GAS1,FLJ45537
rs1547162 0.002719 13 29382862 UBL3 UBL3,LOC440131
rs10853283 0.003112 18 2705727 NDC80 EMILIN2,METTL4,NDC80,SMCHD1
rs7243360 0.003142 18 54105771 NEDD4L ALPK2,NEDD4L
rs347240 0.003296 5 72821340 FOXD1 FOXD1,UTP15,BTF3,ANKRA2,RGNEF
rs6828613 0.003311 4 40994249 LIMCH1 UCHL1,LIMCH1,APBB2
rs6750502 0.00362 2 231991153 ARMC9 ARMC9,B3GNT7,C2orf57,C2orf52,NMUR1,NCL
rs13173742 0.004548 5 95166326 RHOBTB3 SPATA9,GPR150,RHOBTB3,ARSK,RFESD,ELL2,GLRX
rs10039749 0.004586 5 115256241 CDO1 ATG12,COMMD10,CDO1,FLJ90650,AP3S1
rs12657132 0.0046 5 118600296 DMXL1 TNFAIP8,DMXL1
rs9525029 0.004804 13 95045828 DZIP1 DZIP1,DNAJC3,CLDN10
rs9513227 0.004809 13 96737303 MBNL2 RAP2A,MBNL2
rs1648390 0.005065 11 111225282 DIXDC1 C11orf52,PPP2R1B,DLAT,ALG9,C11orf1,CRYAB,SNF1LK2,LOC91893,
HSPB2,DIXDC1
rs2528467 0.005095 7 16486114 SOSTDC1 ANKMY2,LOC442511,SOSTDC1,BZW2,LOC729920
rs11638121 0.00512 15 29212294 TRPM1 TRPM1,MTMR15,KLF13,MTMR10
rs2739733 0.005429 8 18047160 ASAH1 PCM1,ASAH1,NAT1
rs936534 0.005785 2 70428397 PCYOX1 FAM136A,C2orf42,PCYOX1,SNRPG,TIA1,TGFA
rs13144644 0.005873 4 186900916 SORBS2 SORBS2
rs9460922 0.005964 6 10709652 PAK1IP1 MAK,C6orf218,TFAP2A,GCNT2,TMEM14B,PAK1IP1,TMEM14C
rs10113275 0.007136 8 38880340 ADAM9 TACC1,TM2D2,HTRA4,PLEKHA2,ADAM9
rs17029542 0.0077 4 100968373 DNAJB14 DNAJB14,MAP2K1IP1,DAPP1,H2AFZ
rs11189328 0.007749 10 99437994 SFRP5 C10orf132,ANKRD2,CRTAC1,C10orf65,C10orf83,ZFYVE27,UBTD1,MMS19,
SFRP5,C10orf62,AVPI1,PI4K2A
rs9662167 0.007964 1 13824323 PDPN PDPN,PRDM2
rs1452312 0.008027 2 183373406 FRZB NCKAP1,DNAJC10,FRZB
rs9806753 0.008028 15 46953709 EID1 EID1,CEP152,KIAA0256,SHC4
rs11905700 0.008705 20 9220914 PLCB4 PLCB4
rs12051963 0.008999 18 31929324 SLC39A6 SLC39A6,ELP2,C18orf21,P15RS,MOCOS
rs7764938 0.00914 6 144262097 PHACTR2 PHACTR2,LTV1,SF3B5,PLAGL1
rs9824873 0.009229 3 184784468 KLHL24 KLHL6,KLHL24,MCF2L2,YEATS2
rs13131773 0.00958 4 184182880 WWC2 DCTD,WWC2,C4orf38
Human Molecular Genetics, 2010, Vol. 19, No. 12 2479similar signal peptide sequences in 18 of the encoded proteins
(Fig. 8; 72–74). There is growing evidence that signal pep-
tides play a major role in controlling protein sorting and traf-
ﬁcking in the endoplasmic reticulum [ER (75–77)].
Accumulation of mild folding variants of the proteins due to
polymorphic variations/mutations leads to the aggregation of
misfolded proteins, increased ER stress and eventual cell
degeneration. For example, late-onset autosomal dominant
retinal macular degeneration (L-ORMD), which phenotypi-
cally resembles AMD, is caused by mutations in C1QTNF5,
a short-chain collagen gene expressed in the RPE. It has
been proposed that mutant CTRP5 is misfolded, retained in
the ER and subjected to degradation leading to RPE dysfunc-
tion (78). The phenotype of L-ORMD is similar to Sorsby’s
fundus dystrophy caused by mutations in TIMP3. In both
cases, ER stress and abnormal cell adhesion cause cell
degeneration and a failure to clear cellular debris from under
the RPE, which suggests the possibility of immune attack—
as seen in AMD (79).
As RPE is thought to be a critical target for AMD, numer-
ous investigations have focused on regenerating or replacing
damaged RPE from ES cells or from iPS cells. Several
human ES lines can be induced to develop the RPE phenotype
(80–82) and one of these has been used in transplantation
experiments to rescue visual function in RCS rats (83).
However, in the absence of a molecular signature, it is difﬁcult
to assess which in vitro generated RPE lines will retain appro-
priate function after transplantation. The RPE signature gene
set can therefore be a valuable tool in regenerative medicine
for validating the progress of RPE differentiation, propagation
and maintenance. For clinical trials, it would be critical to
conﬁrm that RPE cell lines derived from hES cells exhibit
an expression proﬁle comparable with the native RPE. We
suggest that the signature gene set can be used to monitor
the development to RPE phenotype and, together with func-
tional tests such as polarity and physiology (18,84), can deter-
mine appropriate cell lines for transplantation and rescue
experiments.
In conclusion, we have described a speciﬁc gene signature
of human RPE based on extensive analysis of native and cul-
tured cells. Our analysis of the 154 RPE signature gene set
provides a wealth of information for biological studies,
reveals candidate genes for retinal/macular diseases and
suggests potential molecular markers for assessing the integ-
rity and function of RPE for cell-based therapies.
MATERIALS AND METHODS
Native tissues and cell culture
This research followed the tenets of the Declaration of Hel-
sinki and the guidelines of NIH Institutional Review Board
and written informed consent was obtained from the GWAS
subjects. Human fetal eyes (gestation, 16–18 weeks) were
obtained from Advanced Bioscience Resources (Alameda,
CA, USA) and human adult eyes were obtained from Analyti-
cal Biological Services, Inc. (Wilmington, DE, USA). Human
adult native RPE (anRPE) were obtained from four donors of
Caucasian descent (age 64–89 years old) within 24 h of death
(postmortem time ,12 h). Human fetal native RPE (fnRPE),
retina and human fetal choroid (hfCH) were isolated and
fnRPE were cultured on Primaria
w ﬂasks as described pre-
viously (18). For immunoﬂuorescence localization or ﬂuid
transport experiments, cells were cultured on human ECM-
Figure 8. Structure of signal peptides and protein localization for 18 proteins obtained as the result of cross validation between GWAS and RPE signature studies.
All of the presented peptides have a tripartite structure consisting of a central hydrophobic region (H-core, red), N-terminal hydrophilic region (N-region, green) and
C-terminal ﬂanking region located next to the protein (C-region, blue). Residues predicted to form a-helices are underlined. The H-core is helical in a majority of
sequences and formed by leucine, alanine and valine residues. Protein localization was obtained using the UniProt information resource (http://pir.georgetown.edu)
and sequences were aligned using the Promals3D program (http://prodata.swmed.edu/promals3d/promals3d.php).
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membrane). ARPE-19, a spontaneously transformed RPE
cell line, was maintained under culturing conditions identical
to fetal RPE primary cultures. The initial experimental
design included separate samples of RPE grown on ﬂasks
(passage P0) or inserts (passage P1) coated with ECM. As no
signiﬁcant difference was observed between expression pro-
ﬁles of the cells grown on ﬂasks or inserts (data not shown),
we merged the two data sets for subsequent analysis.
Protein analysis
RPE, retina or choroid cells were lysed in RIPA buffer
(Sigma-Aldrich, St. Louis, MO, USA) containing a proteinase
inhibitor cocktail (Roche, Indianapolis, IN, USA). Protein
extracts (10–15mg) were electrophoresed using 4–12% Bis–
Tris NuPAGE gel and blotted onto nitrocellulose membranes
(Invitrogen, Carlsbad, CA, USA). The blots were incubated
with antibodies against human BEST1, TYRP1 (Abcam,
Figure 9. DCT silencing in hfRPE cultures grown on cell culture inserts using lentiviral-mediated transduction of shRNA. (A) Semi-quantitative evaluation of
western blots of DCT after transduction with different shRNA clones. Labels indicate different clones: NT—non-targeting construct and 38–42 are DCT targeting
shRNA clones. After quantiﬁcation of band intensities and normalization to tubulin, DCT protein expression shRNA transduced cells were calculated relative to that
of the cells transduced with NT shRNA (100%). (B) Transepithelial resistance measurements of conﬂuent hfRPE monolayers grown on inserts transduced with
DCT38 shRNA clones and compared with an NT construct controls (P , 0.05; n ¼ 6). (C–H) Representative immunohistochemistry staining of hfRPE cells
expressing shRNA directed against DCT (F, G, and H) and NT control shRNA (C, D, and E). Lower part of each panel is an en face view of maximum intensity
projection (MIP) through the z-axis. Top part of each panel is a cross-sectional view through the z-plane. Lowest part of DAPI signal (dotted white lines) delineates
the basal membrane. White arrowheads point to hfRPE apical surface. Red: DCT (C, F), ezrin (D, G), actin (E, H). Blue: DAPI-stained nuclei; green: ZO-1 indicates
tight junction location separating apical and basolateral membranes. Transduction of hfRPE cells with DCT38 shRNA dramatically reduced the DCT levels inside
cells (F), reduced and disorganized ZO-1 localization (F and G), and disrupted F-actin ﬁbers to a more diffuse pattern with apical localization (H).
Human Molecular Genetics, 2010, Vol. 19, No. 12 2481Cambridge, MA, USA), CDH3 (Invitrogen), RPE65 (Dr. T. M.
Redmond, NEI, NIH), CHRNA3 (Proteintech group, Inc.,
Chicago, IL, USA), or CRX (Abnova, Walnut, CA, USA).
b-Actin and a-tubulin (Abcam) were used as controls. Immuno-
blot signals were detected using West Dura Chemiluminescence
system (Pierce), imaged using AutochemieTM system (UVP,
Upland, CA, USA), and quantiﬁed using Labworks software.
Immunocytochemistry
hfRPE cultures on cell culture inserts (Transwell; Corning
Costar) transduced with MISSION lentiviral particles were
ﬁxed for 30 min in 4% formaldehyde–PBS on ice, washed
three times with PBS, and permeabilized for 30 min with 0.2%
Triton X-100–PBS. The cells were washed three times with
PBS,stainedwithantibodiesagainstDCT(1:1000,ProteinTech),
ezrin (1:500, Abcam), ZO-1 (1:1500, Invitrogen) overnight at
48C in blocking solution, following by incubated with Alexa
Fluor conjugated secondary antibodies (1:1000, Invitrogen) for
2 h and mounting with Vectashield medium containing DAPI
(VectorLabs). F-actin was stained with Texas Red phalloidin
(Molecular Probes). Stained inserts were imaged for microscopy
(Axioplan 2 with Axiovision 3.4 software with ApoTome; Carl
Zeiss Meditec, Inc., Dublin, CA, USA). Negative controls were
performed with omission of primary antibodies.
Lentivirus transduction
Lentiviruses have the unique ability to infect nondividing cells.
MISSIONTM (Sigma) lentiviral system was used to deliver
speciﬁc short-hairpin RNAs (shRNA) in hfRPE cells to
mediate the levels of DCT expression. Target hfRPE cells were
seeded in a 24-well insert (2 × 10
5/well), grown to conﬂuence
and cultured for 4–6 weeks. Hexadimethrine bromide (8 mg/
ml)wasaddedtoincreasetheefﬁciencyoflentiviraltransduction
(Sigma), and all the transductions were performed at minimum
effective multiplicity of infection of 2. The use of lentivirus
shRNA resulted in 98% transduction efﬁciency. Viral medium
was removed after 24 h of transduction and DCT protein levels
were measure by western blots a week later. Immunocytochem-
isty staining was performed 3 weeks after the transduction. The
functional effects on intact monolayers were evaluated by
measurement of TER using EVOM (Precision Instruments).
RNA proﬁling
RNA was extracted from human tissues and cells using
RNAeasy Kit (Qiagen, Valencia, CA, USA) or total RNA iso-
lation kit (Superarray Biosciences, Frederick, MD, USA). The
panel of human tissues and cell cultures in this study included
brain, melanocytes, colon, intestine, kidney, lung, trachea,
testes, liver, calu-3 cells and a tissue mix, and were obtained
commercially (Ambion First Choice Survey). Concentration
and quality of RNA was determined using Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA) and/or Nano
drop spectrophotometer (Wilmington, DE, USA). All samples
had A(260)/A(280) ratios of the total RNA .2.0, and the ratio
of 28S/18S ribosomal RNA bands was more than 1.8. The
purity of RPE preparations was conﬁrmed by measuring tran-
script levels of rhodopsin. We also conﬁrmed the absence of
several choroid-speciﬁc transcripts (S100A4, RGS5, ACTA2,
ACTN1) in RPE samples. The absence of cross-contamination
was conﬁrmed in retina and choroid samples from the same
eye by measuring RPE65 transcript levels. For the RNA Affy-
metrix chip analysis, we used The Vanderbilt Functional Geno-
mics Shared Resource (FGSR). For each sample, the RNA
integrity was indicated by an RIN number ranging from 0 to
10, with higher numbers indicating higher quality and we used
samples with RIN .7. All four RPE groups (FC, AC, FN and
AN) were deﬁnitively distinguished by the microarray analysis.
Supplementary Material, Figure S1 shows that the RPE tissues
arerelativelyindistinguishablefromeachother,butmostimpor-
tantly they are all clearly segregated from the other tissue types
throughout the body. The relative uniformity of mean gene
expression, from tissue to tissue, and their low variance indi-
catesthatthedataarenotlimitedbyrelativelysmallsamplesize.
The cDNA, reverse-transcribed from total RNA, was used
to generate biotinylated cRNA with a BioArray High Yield
RNA Transcript Labeling Kit (Affymetrix, Santa Clara, CA,
USA). Fifteen micrograms of fragmented cRNA were hybri-
Table 3. Twenty-ﬁve candidate RPE signature genes found in loci associated with retinal disease
Disease locus
a Disease name Chromosomal location
b Candidate RPE genes
LCA9 Recessive Leber congenital amaurosis 1p36 PDPN, KLHL21
CORD8 Recessive cone-rod dystrophy 1q23.1–q23.3 BAT2D1
RP28 Recessive retinitis pigmentosa 2p16–p11 USP34
CRV,HERNS,HVR Dominant hereditary vascular retinopathy 3p21.3–p21.1 CSPG5,SLC6A20,PTPRG
MCDR3 Dominant macular dystrophy 5p15.33–p13.1 SCAMP1,RHOBTB3
BCMAD Dominant macular dystrophy 6p12.3–q16 EFHC1, VEGFA
MDDC Dominant macular dystrophy, cystoid 7p21–p15 SOSTDC1,SEMA3C
OPA6, ROA1 recessive optic atrophy 8q21–q22 LAPTM4B,SDC2
EVR3 Dominant familial exudative vitreoretinopath 11p13–p12 FADS1
CODA1 Dominant cavitary optic disc anomalies 12q13.13–q14.3 ATF,SILV,NAV3
MRST Retinal degeneration, retardation 15q24 CHRNA3
OPA4 Dominant optic atrophy 18q12.2–q12.3 SLC39A6
MCDR5 Dominant macular dystrophy 19q13.31–q13.32 CRX
RP23 X-linked retinitis pigmentosa Xp22 GPM6B,CLCN4, GPR143
aInformation about disease loci collected from RetNet: www.sph.uth.tmc.edu/retnet/
bChromosome location of disease loci.
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plus 2.0 array, Affymetrix).
The signal intensity for each of 54 675 probe sets on the
Affymetrix Human U133 plus 2.0 chips was calculated using
GeneChip
w Operating Software 1.4 (Affymetrix). Affymetrix
probe set signal intensities were median normalized, i.e.
divided by the median of each chip, and log10 transformed.
Normalization and statistical analysis were carried out
using the MSCL Analysts Toolbox (http://abs.cit.nih.gov/
MSCLtoolbox/), a microarray analysis package that consists
of custom-written scripts in the JMP statistical discovery soft-
ware (SAS Institute, Cary, NC, USA), and developed by two
of the co-authors (P.J.M., J.J.B.). Data were collected under
the MIAME compliant format and the raw data have been
deposited in the Gene Expression Omnibus hosted by NCBI
(GEO; http://www.ncbi.nlm.nih.gov/geo/query/) with query
accession no: GSE18811. Visualization of the global relation-
ships among the 30 samples and detection of possible outliers
were facilitated with PCA biplots of the normalized data (85).
Hierarchical clustering of the 30 samples, using all principal
components and Ward’s method, produces a dendrogram
and an ordering of samples into clusters.
Validation of expression data by qRT-PCR
Quantitative mRNA analysis was performed for 150 genes
using RT two real-time pre-developed primer sets (SuperAr-
ray, Frederick, MD, USA). Relative changes in gene
expression were calculated using a variation of the DDCt
method. The DCt is the threshold cycle of the gene Ct value
(copies × 10
5/mg RNA) minus the average of the Ct values
of ﬁve housekeeping genes (B2M, HPRT1, RPL13A,
GAPDH and ACTB). The average DCt was calculated for
each individual group (fc, fn, ac, an) of RPE tissues and for
each of the comparison tissues. There were at least two bio-
logical replicates in each group of RPE tissue.
Derivation of RPE ‘gene signature’
Highly expressed RPE probe sets were identiﬁed in terms of
rEx level, rEx (86). The rEx for an RPE tissue is deﬁned as
the ratio of RPE expression to the median expression of 78
diverse anatomical samples (Genomics Institute of Novartis
Research Foundation tissue data set). This set was augmented
with several additional tissues of local origin (http://biogps.
gnf.org/#goto=welcome). Both the RPE and the Novartis data
were normalized using the log-median transformation. Since
the Novartis data were collected on older Affymetrix U133A
GeneChip, it had only  40% of the number of probe sets in
the newer U133 Plus 2 chip used for the RPE data. A gene is
included as an RPE signature gene if its mean expression
level in all three tissues, native adult and fetal RPE and cultured
fetal RPE, are 10-fold or greater than the median expression for
that gene in the Novartis data set. Each signature gene can have
multiple probe sets in the RPE signature set.
GO analysis
Functional annotation, classiﬁcation and identiﬁcation of sig-
niﬁcantly enriched biological themes of RPE signature genes
were examined using The Database for Annotation, Visualiza-
tion and Integrated Discovery (71) bioinformatics resource
(http://david.abcc.ncifcrf.gov/) and Expression Analysis Sys-
tematic Explorer (EASE) (http://apps1.niaid.nih.gov/david).
GO terminology for ‘biological processes’ (http://www.
geneontology.org/) was used to identify signiﬁcant overrepre-
sentation of functional classes in the RPE signature list, as
described previously (87,88). EASE score or Fisher’s exact
test P-value was used to measure the signiﬁcance of the
gene-enrichment within each biological process category.
Comparison of RPE genes to AMD–GWAS data
To examine possible association of RPE ‘signature’ genes to
AMD, we identiﬁed SNPs within 100 kb of the 5′ and 3′
ends of the RPE ‘signature’ genes and evaluated their associ-
ation with macular degeneration in a recently completed
AMD–GWAS (89). The GWAS data included 2157 AMD
cases and 1150 controls, each examined on 324 067 SNPs
using Illumina Human 370CNV BeadChips. An additional
 2.2 million markers arrays were imputed using HapMap
genotypes and were also examined (90). A total of 33 096
SNPs near 154 RPE signature genes were examined, corre-
sponding to a Bonferroni signiﬁcance threshold of 1.5 ×
10
26. The 33 096 correspond to 4305 independent tag SNPs.
To identify additional SNPs that may be implicated in AMD
pathogenesis, we also evaluated false discovery rates (91)
and inspected quantile–quantile plots for all SNPs.
eQTL analysis
A database of expression quantitative trait loci, obtained by
GWA analysis of SNPs with gene expression levels in lym-
phoblastoid cell lines (30), was searched for regulatory SNPs
associated with RPE ‘signature’ genes. The evidence for
association between each of these potential regulatory SNPs
and AMD was then evaluated based on the data of Chen
et al.( 25). The Dixon et al. data consist of a catalog of associ-
ation between SNPs and transcripts generated by examining
lymphoblastoid cell lines from  400 children.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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